Researchers at University of Birmingham identify new biomarker for cancer therapy response in pediatric patients with solid tumors including Ewing Sarcoma and various sarcomas.
A study by researchers at the University of Birmingham has identified a new biomarker that can predict how children respond to a specific cancer therapy, particularly effective against Ewing Sarcoma and other types of solid tumors. The research, conducted as part of the eSMART Trial and supported by the Cancer Research UK Clinical Trials Unit (CRCTU), recruited 70 patients from four countries—UK, France, the Netherlands, and Spain—and treated them with a targeted therapy.
Of these 70 patients, 66 received treatment across all four sites. The study focused on solid tumors, with 36 of those patients having Ewing Sarcoma and 34 having various other types of sarcomas and central nervous system tumors. This new biomarker could potentially help doctors tailor treatments more effectively for these children, improving outcomes and reducing side effects.
The findings suggest that this biomarker may be useful in identifying which pediatric cancer patients are most likely to benefit from the therapy being studied. The next steps will involve further clinical trials to validate these results and explore how the biomarker can guide treatment decisions.
